Long-term treatment of acromegaly with the somatostatin analogue SR-lanreotide (Q78094430)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10435849%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

title

Long-term treatment of acromegaly with the somatostatin analogue SR-lanreotide (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10435849%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

author name string

M Suliman

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10435849%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

R Jenkins

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10435849%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

R Ross

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10435849%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

T Powell

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10435849%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

R Battersby

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10435849%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

D R Cullen

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10435849%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

publication date

1 June 1999

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10435849%20AND%20SRC:MED&resulttype=core&format=json

Journal of Endocrinological Investigation

10 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10435849%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

volume

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10435849%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10435849%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

page(s)

409-418

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10435849%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/bf03343583

10 December 2019

exact match

0 references

cites work

Determinants of clinical outcome and survival in acromegaly

1 reference

12 December 2020

1 reference

12 December 2020

The sensitivity of growth hormone secretion to medical treatment in acromegalic patients: influence of age and sex.

1 reference

12 December 2020

Sandostatin LAR in acromegalic patients: long-term treatment

1 reference

12 December 2020

1 reference

12 December 2020

[Treatment of acromegaly with a new slow release somatostatin analog, lanreotide]

1 reference

12 December 2020

A monoclonal antibody to human insulin-like growth factor-I: characterization, use in radioimmunoassay and effect on the biological activities of the growth factor

1 reference

12 December 2020

The growth hormone responses to octreotide in acromegaly correlate with adenoma somatostatin receptor status

1 reference

12 December 2020

Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide

1 reference

12 December 2020

Pharmacokinetics and efficacy of a long-acting formulation of the new somatostatin analog BIM 23014 in patients with acromegaly

1 reference

12 December 2020

Growth hormone, body composition and somatomedin C after treatment of acromegaly

1 reference

12 December 2020

Cholelithiasis and acromegaly: therapeutic strategies.

1 reference

12 December 2020

Pharmacokinetic study and effects on growth hormone secretion in healthy volunteers of the new somatostatin analogue BIM 23014

1 reference

12 December 2020

Depot long-acting somatostatin analog (Sandostatin-LAR) is an effective treatment for acromegaly

1 reference

12 December 2020

Acromegaly: what constitutes optimal therapy?

1 reference

12 December 2020

Pharmacokinetics and efficacy of the long-acting somatostatin analogue somatuline in acromegaly

1 reference

12 December 2020

Assessment of GH status in acromegaly using serum growth hormone, serum insulin-like growth factor-1 and urinary growth hormone excretion.

1 reference

12 December 2020

Carbohydrate tolerance and serum lipids in acromegaly before and during treatment with high dose octreotide.

1 reference

12 December 2020

Consensus statement: benefits versus risks of medical therapy for acromegaly

1 reference

12 December 2020

The effect of a new slow-release, long-acting somatostatin analogue, lanreotide, in acromegaly.

1 reference

12 December 2020

Somatostatin receptors and disease: role of receptor subtypes

1 reference

12 December 2020

Performance of proficiency survey samples in two immunoradiometric assays of human growth hormone and comparison with patients' samples

1 reference

12 December 2020

Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients--a clinical research center study.

1 reference

12 December 2020

An audit of outcome of treatment in acromegaly.

1 reference

12 December 2020

Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group

1 reference

12 December 2020

Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the International Multicenter Acromegaly Study Group

1 reference

12 December 2020